The potential role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in oncology has drawn interest due to their ability to lower glucose, adiposity, insulin resistance, and systemic inflammation—factors associated with cancer progression.1 The impact of glucose-lowering drugs (GLDs) on cancer survival remains inconclusive. This evidence concerns the gene GLP1R and cancer.